Mahana Therapeutics

Build or buy: How should new DTx players be developing their digital treatments?
By Dave Muoio | 04:50 pm | February 12, 2021
MobiHealthNews spoke with Pear Therapeutics, Click Therapeutics and DTx newcomer Mahana Therapeutics to discuss whether in-licensing is the way to go for those just entering the space.
CBT digital therapeutic for IBS patients receives FDA De Novo clearance (Updated)
By Dave Muoio | 04:50 pm | December 08, 2020
Mahana Therapeutics' Parallel is a three-month digital treatment that logs patients' symptoms to deliver relevant guidance and teach them condition-management skills.